Achilles Therapeutics plc (ACHL) Reports In-Line Q2 EPS

Achilles Therapeutics plc (NASDAQ: ACHL) reported Q2 EPS of ($0.41), in-line with the analyst estimate of ($0.41).

For earnings history and earnings-related data on Achilles Therapeutics plc (ACHL) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c
• William Blair Downgrades Cardiff Oncology (CRDF) to Market Perform